The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20210526: Craveability Parent LLC; Zachary W. McLeroy
20210419: Starboard Value and Opportunity Fund Ltd.; Commvault Systems, Inc.
20210483: Park River Holdings, L.P.; The Resolute Fund III, L.P.
2012001 Informal Interpretation
2012002 Informal Interpretation
FTC Staff Comment to the CFPB, Regarding Regulation B, the Implementing Regulation of the Equal Credit Opportunity Act
20210443: American Securities Partners VIII, L.P.; LSF9 Cypress LP
20210395: Summit Partners Growth Equity Fund IX-A, L.P.; Andrew Bialecki
20210411: GTCR Fund XIII/B LP; JSSI Holdings, LLC
20210426: Bain Capital Fund XII, L.P.; Kelso Hammer Co-Investment, L.P.
20210382: Summit Partners Growth Equity Fund IX-B, L.P.; Andrew Bialecki
20210386: Stonepeak Infrastructure Fund IV (AIV II) L.P; Radiate Holdings, L.P.
20210393: Thomas G. Dundon; Callaway Golf Company
20210394: Sun Capital Partners VII, L.P.; Gauge Fund LP
20210335: Addus HomeCare Corporation; Stonehenge Opportunity Fund IV, LP
20210352: TD Greystone Infrastructure Fund (Canada) L.P. I; Silicon Ranch Corporation
20210367: Riverstone Global Energy and Power Fund VI, L.P.; Macquarie Infrastructure Corporation
A.S. Research, LLC (Synovia)
The marketers of a dietary supplement called Synovia agreed to settle FTC charges by halting the deceptive tactics they allegedly used to mislead consumers into thinking Synovia could treat arthritis and alleviate joint pain. In December 2020, the Commission announced it was returning almost $775,000 to consumers who both the deceptively marketed product.